Workflow
Pharmaceuticals
icon
Search documents
Ligand(LGND) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:32
Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorJoe Pantginis - Managing DirectorJoohwan Kim - Assistant VP of BiotechnologyLauren Hay - VP of Strategic Planning and Investment AnalyticsMelanie Herman - Executive Director of Investor RelationsTavo Espinoza - CFOTodd Davis - CEOConference Call ParticipantsJohn Vandermosten - Senior AnalystMatt Hewitt - Senior Research AnalystPete Lucas - AnalystTrevor Allred - Ex ...
Catalyst Pharmaceuticals(CPRX) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:32
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsJeff Del Carmen - EVP and Chief Commercial OfficerMike Kalb - EVP and CFORich Daly - President and CEONone - Company RepresentativeConference Call ParticipantsJason Dorr - Research AnalystKeith Savon - AnalystLuke Herrmann - Research AnalystPavan Patel - Biopharma Equity Research AnalystNone - AnalystNone - AnalystOperatorGood morning, thank you for standing by. My name is John, and I will be you ...
Novavax(NVAX) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:32
Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...
Novavax(NVAX) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:32
Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...
Catalyst Pharmaceuticals(CPRX) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:30
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good morning, thank you for standing by. My name is John, and I will be your conference operator today. At this time, I would like to welcome everyone to the Catalyst Pharmaceuticals Fourth Quarter and Full Year 2025 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. If you would like ...
Viatris(VTRS) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:30
Viatris (NasdaqGS:VTRS) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker10Good morning, and welcome to the Viatris Q4 2025 earnings call. Today, all participants are in a listen-only mode. Should you need assistance during today's call, please signal for a conference specialist by pressing the star key, followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your touchtone phone. To withdraw your question, please p ...
Collegium Pharmaceutical Q4 Earnings Call Highlights
Yahoo Finance· 2026-02-26 14:16
Chief Commercial Officer Scott Dreyer said Jornay delivered record prescription volume in both the fourth quarter and full year 2025. In the fourth quarter, more than 200,000 prescriptions were written, up 16% year-over-year, and more than 760,000 prescriptions were written in 2025, up 20%. Dreyer added that average weekly prescriptions increased to approximately 16,600 in December from about 13,800 in July, and he said momentum continued into January at approximately 16,800 weekly prescriptions despite typ ...
Indivior PLC(INDV) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:02
Indivior (NasdaqGS:INDV) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristian Glennie - DirectorJason Thompson - VP of Investor RelationsJoe Ciaffoni - CEO and DirectorPatrick Barry - CCORyan Preblick - CFOThibault Boutherin - Equity Research - Executive DirectorConference Call ParticipantsBrandon Folkes - Managing Director and Senior Equity Research AnalystChase Knickerbocker - Senior Equity Research AnalystDavid Amsellem - Managing Director and Senior Research AnalystDennis Di ...
BeiGene(BGNE) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:02
BeOne Medicines (NasdaqGS:BGNE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAaron Rosenberg - CFOAmit Aggarwal - Chief Medical Officer of HematologyDan Maller - VP of Investor RelationsJohn V. Oyler - Co-Founder, Chairman and CEOLai Wang - President and Global Head of Research & DevelopmentMark Lanasa - SVP and Chief Medical OfficerMatt Shaulis - General Manager of North AmericaSean Laaman - Executive DirectorXiaobin Wu - President and COOZhihong Chen - Managing DirectorNone - Co ...
Collegium Pharmaceutical(COLL) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:02
Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorColleen Tupper - CFOIan Karp - Head of Investor RelationsJeevan Larson - Equity Research AssociateScott Dreyer - Chief Commercial OfficerVikram Karnani - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystOperatorGreetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings co ...